NCLT Approves First Motion for NKURE-Eyestem Amalgamation

The National Company Law Tribunal (NCLT) Bengaluru Bench has approved the first motion application for the amalgamation of NKURE Therapeutics and Eyestem Research.
The order directs the companies to convene meetings of equity and preference shareholders on May 19, 2026, to approve the scheme of amalgamation.
The scheme involves a share swap of 72 shares in NKURE for 1 share in Eyestem, with all employees to be transferred to the new entity.